Form 4: Alkermes Director Nancy Snyderman Reports Equity Activity

Director Nancy Snyderman exercised restricted stock units and received new equity grants in Alkermes plc.

Summary

• Director Nancy Snyderman acquired 6,142 ordinary shares through the vesting of restricted stock units on May 21, 2026.
• 1,475 shares were withheld by the company to satisfy tax obligations at a price of $36.95 per share.
• The director received a new grant of 11,538 non-qualified stock options exercisable at $36.98.
• The director received a new grant of 5,409 restricted stock units.
• Following these transactions, the director holds 15,395 shares directly and 20,783 shares indirectly via the Snyderman Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and equity management.

Positives

• Director maintains a significant long-term stake in the company through both direct and trust-based holdings.
• Equity-based compensation aligns director interests with shareholder value creation.

Negatives

• Tax withholding resulted in a reduction of the total shares acquired from the RSU vesting.

Risks

• Future value of stock options is dependent on the company's share price performance exceeding the $36.98 exercise price.

Future Outlook

The new equity awards vest in full on the earlier of the one-year anniversary of the grant or the date of the next annual general meeting occurring at least 50 weeks after the grant date.

Management Comments

• No direct management commentary provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that routine equity grants and RSU vestings for board members are standard corporate governance practices in the biopharmaceutical sector to ensure long-term alignment with shareholder interests.

Comparison to Industry Standards

• The use of RSUs and stock options as director compensation is consistent with standard practices for mid-to-large cap biotech firms like Alkermes.
• The vesting schedule of approximately one year is standard for director equity awards.

Stakeholder Impact

• Minimal impact on shareholders as these are standard equity compensation disclosures.

Next Steps

• Vesting of the newly granted 11,538 stock options and 5,409 RSUs on or before May 20, 2027.

Key Dates

Keywords

Alkermes, ALKS, Insider Trading, Form 4, Equity Compensation, Biotech